TMPRSS2 and prostate adenocarcinoma: To find DETGs that could drive cancer in the other 38 PRAD samples with TMPRSS2-ERG fusion not retaining functional domains, we performed DETG analysis by comparing 38 samples with out-of-frame fusion versus the 21 in-frame fusion samples (|log2(Fold change, FC)| ≥ 0.585, q-value < 0.2, and Supplementary Table 3).